Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy

This publication has 31 references indexed in Scilit:

• Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2018
• 23 Evidence for antigen-driven TCRB chain convergence in the tumourinfiltrating t cell repertoire of 148 research subjects with melanoma
  ESMO Open, 2018
• Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
  New England Journal of Medicine, 2018
• Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
  Therapeutic Advances in Medical Oncology, 2018
• Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
  Science Translational Medicine, 2017
• Estimating T-cell repertoire diversity: limitations of classical estimators and a new approach
  Philosophical Transactions of the Royal Society B: Biological Sciences, 2015
• Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
  PLOS ONE, 2012
• Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain VαVβ fragments
  Molecular Immunology, 2009
• A Direct Estimate of the Human αβ T Cell Receptor Diversity
  Science, 1999
• Structure and specificity of T cell receptor gamma/delta on major histocompatibility complex antigen-specific CD3+, CD4-, CD8- T lymphocytes.
  Journal of Experimental Medicine, 1988